

Social and implementation research for ending AIDS in Africa

“We need to do our utmost so that the benefits of the new treatments can reach those poorest people in Africa and in the rest of the world” said Jacques Chirac, former French President, at the tenth International Conference on AIDS and STIs in Africa (ICASA), held in December, 1997, in Abidjan, Cote d'Ivoire. 20 years on, Abidjan is again hosting ICASA, with one aim: “Africa: ending AIDS—delivering differently”.

In two decades, new funding mechanisms have been developed and antiretroviral therapy (ART) has been scaled up exponentially. ART has been proven efficient in reducing mortality and morbidity, HIV transmission,¹ and HIV acquisition.² Social science contributed to show that access to ART was feasible, efficient, and acceptable in Africa.³ Modelling research suggested that a universal test-and-treat strategy could potentially stop HIV transmission and end AIDS⁴—the goal of UNAIDS's 90-90-90 target for 2020.

However, we are still facing major gaps. Biomedical innovations will be crucial, but not sufficient alone. Innovations in terms of intervention implementation, delivery models, and public health policies are urgently required. Such challenges are not just operational, logistic, or politic. Beyond effectiveness, we need empirical and theoretical knowledge about implementation.⁵ We also need social science research, both fundamental and operational, to analyse social, cultural, political, and structural processes that still limit access to prevention and care.

Long-term perspective is needed to understand present limitations of HIV services, despite the huge funding devoted to HIV response by global institutions. How global health policies could jeopardise local response in some areas? Why perceived stigma

is still a major barrier to care and services as it was 20 years ago? This issue is particularly true for western and central Africa, which received historically less attention than eastern and southern Africa⁶ and where gaps are more pronounced: among people living with HIV in 2016, only 42% knew their status, 35% were on treatment, and 25% were virally suppressed in western and central Africa, versus 76%, 60%, and 50%, respectively, in eastern and southern Africa.⁷

These issues were raised at the Social Science and HIV/AIDS in Sub-Saharan Africa conference, hosted in Abidjan in December, 2016. To fully play their part, social and implementation sciences must embrace the key questions raised by contemporary epidemics and that cannot be solved by biomedical science alone, including stigma, therapeutic failure, people-centred approaches, ageing of people living with HIV, integration of HIV services, governance and funding, and implementation of universal health coverage. Dedicated funding for coordination, research networks, and both operational and fundamental social science research is essential.

We, scientists in social and implementation science, on behalf of the Abidjan 2016 conference scientific committee, would like to reaffirm the importance of multifaceted and plural social sciences and to keep such research on the international scientific agenda, in particular for western and central Africa. We hope that the 2017 ICASA conference held in Abidjan this week will provide a forum to discuss such matters.

We declare no competing interests. We are members of the Social Science and HIV/AIDS in Sub-Saharan Africa Conference Scientific Committee. The full list of committee members is available online.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

*Joseph Larmarange, Khoudia Sow, Christophe Broqua, Francis Akindès, Anne Bekelynyck, Mariatou Koné
joseph.larmarange@ceped.org

Centre Population et Développement (UMR 196 Paris Descartes IRD), SageSud ERL Inserm 1244, Institut de Recherche pour le Développement, Paris, France (JL); CRCF, Dakar, Sénégal (KS); Department of Anthropology and Sociology, Graduate Institute of International and Development Studies, Geneva, Switzerland (CB); Chaire Unesco de bioéthique, Université Alassane Ouattara, Bouaké, Côte d'Ivoire (FA); Programme PAC-CI, Abidjan, Côte d'Ivoire (AB); and Institut d'ethnoscologie, Université Félix Houphouët-Boigny and Ministère de la solidarité, de la cohésion sociale et de l'indemnisation des victimes, Abidjan, Côte d'Ivoire (MK)

- 1 Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; **365**: 493–505.
- 2 Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. *AIDS Lond Engl* 2016; **30**: 1973–83.
- 3 Desclaux A, Ciss M, Taverne B, et al. Access to antiretroviral drugs and AIDS management in Senegal. *AIDS Lond Engl* 2003; **17** (suppl 3): S95–101.
- 4 Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet* 2009; **373**: 48–57.
- 5 Ridde V, Olivier de Sardan JP. The implementation of public health interventions in Africa: a neglected strategic theme. *Médecine Santé Trop* 2017; **27**: 6–9.
- 6 The Lancet HIV. Initiatives to fill the gaps in Africa's AIDS response. *Lancet HIV* 2017; **4**: e321.
- 7 UNAIDS. Ending AIDS, progress towards the 90-90-90 targets: global AIDS update 2017. Geneva: UNAIDS, 2017.



For more on ICASA 2017 see <http://icasa2017cotedivoire.org/>

For the full list of committee members see <https://abidjan2016.sciencesconf.org/resource/page/id/1>